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Abstract
Prosthetic joint infection remains one of the most devastating complications of arthroplasty. Debridement and retention of the prosthe-
sis is an attractive management option in carefully selected patients. Despite this, there are no data investigating the cost of this man-
agement modality for prosthetic joint infections. The aim of this case–control study was to calculate the cost associated with
debridement and retention for management of prosthetic joint infection compared with primary joint replacement surgery without
prosthetic joint infection. From 1 January 2008 to 30 June 2010, there were 21 prosthetic joint infections matched to 42 control
patients. Controls were matched to cases according to the arthroplasty site, age and sex. Cases had a greater number of unplanned
readmissions (100% vs. 7.1%; p <0.001), more additional surgery (3.3 vs. 0.07; p <0.001) and longer total bed days (31.6 vs. 7.9 days;
p <0.001). In addition they had more inpatient, outpatient and emergency department visits (p <0.001, respectively). For patients with
prosthetic joint infection the total cost, including index operation and costs of management of the prosthetic joint infection, was 3.1
times the cost of primary arthoplasty; the mean cost for cases was Australian dollars (AUD) $69 414 (±29 869) compared with
$22 085 (±8147) (p <0.001). The demand for arthroplasty continues to grow and with that, the number of prosthetic joint infections
will also increase, placing signiﬁcant burden on the health system. Our study adds signiﬁcantly to the growing body of evidence
highlighting the substantial costs associated with prosthetic joint infection.
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Introduction
Arthroplasty has led to signiﬁcant health beneﬁts for patients
with arthritis [1]. United States Medicare data suggest that
the demand for joint replacement surgery will increase by
673% and 174% for knee and hip arthroplasty, respectively, by
2030 [2]. Infection of the prosthesis remains one of the major
complications of this surgery. While prosthetic joint infection
remains an uncommon adverse outcome (1–3%), it is associ-
ated with signiﬁcant morbidity, prolonged hospitalizations,
multiple operations and intensive medical and nursing care
[1]. Aside from the impact on the patient, there are also sig-
niﬁcant costs to the health system [3]. Despite this there are
very few data on the cost of prosthetic joint infection, particu-
larly the cost of debridement and retention, which is the
mainstay of therapy in Victoria, Australia.
Patients and Methods
Aim
The aim of this study was to calculate the costs associated
with prosthetic joint infection in a cohort of patients
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managed with debridement and retention of the prosthesis
compared with patients undergoing primary joint replace-
ment surgery without prosthetic joint infection.
Study design
This was a case–control study at a single institution in Mel-
bourne, Australia.
Study population
The study was conducted at St Vincent’s Hospital Melbourne
(SVHM), a metropolitan tertiary hospital afﬁliated with the
University of Melbourne. The Department of Orthopaedic
Surgery at SVHM currently comprises 17 orthopaedic sur-
geons collectively performing over 800 prosthetic joint
replacements per year. The study population comprised all
patients who had primary total knee or hip arthroplasty
between 1 January 2008 and 30 June 2010. Data were
extracted from the SVHM arthroplasty registry, which has
been described elsewhere [4]. In brief, the registry collects
detailed information on all patients undergoing arthroplasty
at the Department of Orthopaedics, including patient demo-
graphics, co-morbidities and medications, as well as informa-
tion about their surgery, their post-operative course and any
complications. The database contained information on the
1514 primary prosthetic joint replacements performed over
the study duration. No patient was lost to follow-up over
the study period. All patients in the registry had 12 months
follow-up data, except for 16 patients (nine total knee
replacements and seven total hip replacements) who died
from causes unrelated to the arthroplasty surgery within the
year following surgery.
At SVHM, patients with early (occurring within 3 months
of implantation) and haematogenous prosthetic joint infection
were managed according to a protocol established through
collaboration between the infectious diseases and orthopae-
dic departments [1]. Patients with proven or suspected early
or haematogenous prosthetic joint infections were admitted
under the orthopaedic department and underwent prompt
arthrotomy and aggressive debridement. Patients typically
undergo a total of three arthrotomies and debridement
[5,6]. In general, patients received a short course of intrave-
nous antibiotics (typically 10–14 days) before commencing
oral antibiotics with activity against bacteria dwelling in the
bioﬁlm. Patients were typically continued on oral antibiotic
therapy for 6–12 months, with intensive infectious diseases
and orthopaedic outpatient follow-up. Outcomes for patients
managed according to this protocol have been previously
published [5–7].
Eligible cases were patients who developed a prosthetic
joint infection within the ﬁrst 12 months following surgery. In
addition, the entirety of the patient’s management was under-
taken at SVHM with a minimum of 12 months follow-up. The
deﬁnition of prosthetic joint infection was consistent with the
CDC deﬁnition of organ space surgical site infection [8].
Controls were deﬁned as patients who did not develop
prosthetic joint infection after at least 12 months of follow-
up and selected as the next patient by date of surgery, who
underwent the same procedure (knee or hip replacement),
matched by age at operation and sex. Two controls were
matched to every case.
Costs
Cost data in Australian dollars (AUD) were derived from
administrative databases maintained by SVHM. Like all Aus-
tralian public hospitals, SVHM routinely tracks all services
provided to individual inpatients and assigns relevant service
costs. Services comprise speciﬁc, individualized items, such as
medical imaging, pharmacy, pathology and surgical proce-
dures, including prostheses used and operative time, as well
as more general care, such as time spent on wards and the
costs of consultation by medical, nursing and allied health
staff. This method of costing is known as the ‘bottom-up’
approach. For the present study, total inpatient costs associ-
ated with the index surgery were collected, including inpa-
tient rehabilitation costs, as well as costs associated with any
readmissions in the following 12 months, with the total com-
bined costs deﬁned herein as ‘episode of care’ costs. We
deﬁned ‘episode of care’ in accordance with the National
Library of Medicine, Medical Subject Headings (MeSH) deﬁni-
tion [9]. Index surgery costs were inclusive of all inpatient
costs associated with index surgery from admission (includ-
ing admission to rehabilitation) until discharge to home. Epi-
sode of care costs were inclusive of all index surgery costs
as well as all associated readmissions to hospital or the
emergency department within 12 months of the index proce-
dure. At SVHM all patients with prosthetic joint infections
are followed-up in the infectious diseases clinics. All antibiot-
ics are dispensed by the infectious diseases physician and
provided by the hospital outpatient pharmacy. Therefore all
costs associated with antibiotic prescription are captured. In
addition, all arthroplasty patients are followed-up in the
orthopaedic clinic. Cost data were extracted by an adminis-
trative staff member at SVHM, who was independent of the
study and blinded to the patients’ outcomes.
The perspective of the above-mentioned costs was that of
the government, predominantly the state (Victorian) govern-
ment and to a lesser extent the federal government. In Aus-
tralia, public hospitals are fully funded by the two levels of
government. There are no out-of-pocket expenses for
patients.
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Data capture
Readmission data were captured via ongoing surveillance of
patients using several methods. Following the index surgery,
all individual patient medical records were reviewed after each
outpatient appointment and all related readmissions were
recorded in the joint replacement registry. These data were
cross-referenced with all admissions recorded on the hospi-
tal’s electronic patient administration system. All readmissions
that occurred within 90 days of the index surgery were con-
sidered to be related admissions. All orthopaedic readmissions
beyond 90 days other than for a planned elective procedure
not involving the original joint replacement were also consid-
ered readmission related to the index procedure. Readmis-
sions to other units within the hospital beyond 90 days were
assessed individually and only those readmissions clearly unre-
lated to the index surgery were excluded. For example, this
occurred when patients with a medical condition that existed
prior to undergoing arthroplasty, required admission for
ongoing medical management of that pre-existing condition.
The Charlson co-morbidity index (CCI) is a widely used
and validated measure consisting of a weighted scale of 17
co-morbidities expressed as a summative score, which is
derived from both the number and seriousness of co-morbid
diseases [10]. The CCI was calculated using co-morbidity
data recorded during the pre-operative medical and anaes-
thetist assessments on the day of surgery and subsequently
age adjusted.
The socio-economic indexes for areas (SEIFA) is a tool
developed by the Australian Bureau of Statistics allowing for
the assessment of the level of social and economic well-being
in a geographical region based upon information from the
2006 census. SEIFA focuses on four indexes to provide a
general measure of socio-economic status [11].
Statistical analysis
Cases and controls were compared using summary statistics.
Descriptive analyses were based on percentages and frequen-
cies for categorical variables, and mean and standard devia-
tion (SD), or medians and interquartile range (IQR) if the
data were skewed, for continuous variables. The
Mann–Whitney U-test and Student’s t-test were used for
comparison of continuous variables and Fisher’s exact test
and chi-squared test were used for categorical variables. Dif-
ferences were considered statistically signiﬁcant at p <0.05.
All analysis was performed using STATA 11.0 software (Stata-
Corp, College Station, TX, USA).
Ethics approval
Both the arthroplasty registry and present study were
approved by the SVHM Human Research Ethics Committee.
Results
Over the study period there were 21 patients with pros-
thetic joint infection identiﬁed (nine prosthetic knee and 12
prosthetic hip replacements). No cases of infection were
excluded, with an overall infection rate of 1.4% (21/1514).
Baseline demographic and co-morbidity data are outlined in
Table 1. Cases were followed for a median of 19 months
(IQR 14–21) from the date of diagnosis of infection. At the
time of manuscript preparation, only one patient had
experienced treatment failure requiring a two-stage
exchange, therefore 95% of patients remained free from
treatment failure.
There were no differences between cases and controls
with respect to co-morbidities, operative factors, length of
initial admission and rehabilitation admission. The only
TABLE 1. Demographic co-morbidity and operative data for
case and control patients
Variable
Control
(n = 42)
Case
(n = 21) p value
Age (years)a 70.2 (8.3) 70.0 (8.3) 0.9
Female genderb (%) 22 (52.3) 11 (52.3) 1.0
Aetiologyb (%)
Primary arthroplasty 40 (95.2) 19 (90.5) 0.5
Aseptic revision 2 (4.8) 1 (4.8)
Septic revision 0 (0) 1 (4.8)
Joint replaced (%)
Knee 18 (42.9) 9 (42.9) 1.0
Hip 24 (57.1) 12 (57.1)
Body mass index (kg/m2)a 31.1 (6.1) 33.3 (7.2) 0.2
Diabetes mellitusb (%) 5 (11.9) 4 (19.0) 0.4
Hypertensionb (%) 20 (47.6) 12 (57.1) 0.5
Cardiovascular
diseaseb (%)
8 (19.0) 3 (14.3) 0.6
Asthma/chronic obstructive
airways diseaseb (%)
4 (9.5) 3 (14.3) 0.6
Oncologyb (%) 5 (11.9) 4 (19.0) 0.8
Smoker (ex and current)b (%) 14 (33.3) 14 (66.7) 0.01
SEIFAc 6.5 (3–8) 7 (5–10) 0.08
Age-adjusted CCIc 0 (0–4) 2 (0–4) 0.2
American Society of Anesthesiologists (ASA)b (%)
1 1 (2.4) 1 (4.8) 0.4
2 23 (54.7) 8 (38.1)
3 17 (40.5) 12 (57.1)
4 1 (2.4) 0 (0)
Number of co-morbiditiesa 2.6 (0.3) 2.7 (0.2) 0.3
Operation time from incision
to wound closure (skin-to-
skin time in minutes)c
95 (85–105) 100 (75–110) 0.9
Discharge destinationb (%)
Home 37 (88.1) 17 (81.0) 0.8
Rehabilitation 5 (11.9) 4 (19.0)
Number of patients with
non-infectious
complicationsb (%)
10 (23.8) 6 (28.6) 0.7
Intensive care unit
admission
2 (4.8) 1 (4.8)
Deep venous thrombosis 2 (4.8) 1 (4.8)
Post-operative confusion 3 (7.1) 0
Rapid atrial ﬁbrillation 1 (2.4) 0
Post-operative shingles 0 1 (4.8)
Haemarthrososis 1 (2.4) 0
Superﬁcial surgical site infection 1 (2.4) 3 (7.1)
aMean (standard deviation).
bFrequency (%)
cMedian (interquartile range).
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exception was smoking; more patients with prosthetic joint
infection had a history (current and ex-smoker) of cigarette
smoking (p 0.01). The implants used for the index arthro-
plasty procedures were purchased from four different manu-
facturers. The type of knee or hip implant used varied, but
individual surgeons did not alter their manufacturer or
implant types during the study time-frame. There was no dif-
ference in non-infectious complications between the two
groups (23.8% vs. 28.6%; p 0.7).
Resource utilization for cases and controls is outlined in
Table 2. Cases were more likely to have unplanned readmis-
sion (100% vs. 7.1%; p <0.001), with a greater length of stay
(LOS) for readmission (22 days vs. 0 days; p <0.001). They
were more likely to need additional surgery (100% vs. 7.1%;
p <0.001). Unplanned surgery in the control group included
one patient requiring a permanent pacemaker insertion, one
patient requiring prosthesis manipulation under anaesthesia
and one patient requiring arthroscopy of their prosthetic
joint to exclude infection. Aside from surgical debridement
for management of the prosthetic joint infection, none of the
cases required additional surgical procedures. Overall, cases
had longer total bed days (31.6 vs. 7.9 days; p <0.001). In
addition, they had more inpatient, outpatient and emergency
department visits (2 vs. 1, p 0.004; 9.9 vs. 2.9, p <0.001; 1.2
vs. 0.1, p <0.001; respectively).
Cost data for cases and control patients are outlined in
Table 3. Overall, the total cost for patients with prosthetic
joint infection was signiﬁcantly higher; the mean cost for
cases was AUD $69 414 (±29 869), compared with $22 085
(±8147) (p <0.001). Across all areas of patient care, cases
had signiﬁcantly higher costs, except for costs associated
with the prosthesis, and coronary and intensive care
admission costs.
Discussion
In this study, we examined the economic impact of arthro-
plasty infection managed by debridement and retention. The
results of this current study highlight the substantial costs
associated with prosthetic joint infection, with the total direct
costs of infection managed by debridement and retention
being 3.1 times higher compared with primary arthroplasty.
A number of other published studies have attempted to
quantify the direct costs associated with prosthetic joint
infections. Bozic et al. compared the direct medical costs in
three distinct groups of patients: patients undergoing primary
hip arthroplasty, patients undergoing two-stage exchange for
prosthetic hip infections and patients undergoing revision of
prosthetic hip joint for aseptic loosening. In this study, the
cost of prosthetic joint infection managed by two-stage
exchange was 2.8 times and 4.8 times greater than aseptic
revision and primary arthroplasty, respectively (p <0.001
both groups). The mean total for inpatient costs in the
patients with prosthetic joint infection was US$96 166
(± 60 664) and outpatients costs were US$48 348
(± 27 965). When compared with our study, patients with
prosthetic joint infections in the Bozic study had similar
length of hospitalization (28.2 days vs. 31.6 days) and number
of procedures (3.69 vs. 3.3). However, patients in the study
TABLE 2. Resource utilization data for case and control
patients
Variable
Control
(n = 42)
Case
(n = 21) p value
Initial LOS (days)a 5.5 (4–7) 6 (4–7) 0.7
LOS rehabilitation (days)b 0 (0–17) 0 (0–12) 0.9
Unplanned readmission (%) 3 (7.1) 21 (100) <0.001
Readmission LOS (days)b 0 (0–3) 22 (4–63) <0.001
Total bed daysc 7.9 (0.8) 31.6 (3.5) <0.001
Unplanned proceduresd (%) 3 (7.1) 21 (100) <0.001
Number of proceduresc 0.07 (0.3) 3.3 (0.7) <0.001
Number of inpatient visitsa 1 (1–2) 2 (1–3) 0.004
Number of emergency visitsc 0.1 (0.4) 1.2 (0.9) <0.001
Number of outpatient visitsc 2.9 (1.6) 9.9 (3.7) <0.001
Statistically signiﬁcant p value (<0.05).
aMedian (interquartile range).
bMedian (minimum and maximum values).
cMean (standard deviation).
dFrequency (%).
LOS, length of stay.
TABLE 3. Costing data for cases and control patients (Aus-
tralian dollars)
Controls
(n = 42)
Cases
(n = 21) p value
Total inpatienta 20 815
(17 120–22 994)
52 747
(41 540–70 535)
<0.001
Medicalb 1589 (1409) 8364 (4452) <0.001
Nursingb 7184 (3810) 25 817 (18 240) <0.001
Operating theatrea 10 251
(8465–11 090)
17 410
(15 473–18 351)
<0.001
Prosthesisb 6852 (2890) 7648 (7648) 0.3
Intensive care unitc 0 (0–5773) 0 (0–2532) 1.0
Coronary care unitc 0 (0–1106) 0 (0–0) 0.5
Allied healthb 1433 (1059) 3401 (2551) 0.001
Medical imaginga 59 (54–113) 255 (177–917) <0.001
Pathologya 173 (96–409) 1569 (1227–2679) <0.001
Pharmacya 304 (263–461) 2191 (1629–4207) <0.001
Hospital in
the homea
430 (0–1098) 1490 (76–2140) 0.02
Total outpatienta 346 (255–545) 4061 (1922–9141) <0.001
Medicala 21 (0–59) 827 (556–1026) <0.001
Nursinga 255 (186–255) 406 (208–560) 0.03
Allied healtha 0 (0–32) 40 (18–214) 0.002
Medical imagingc 0 (0–412) 110 (0–1512) <0.001
Pathologyc 0 (0–233) 134 (0–954) <0.001
Pharmacya 0 (0–1) 1694 (222–5172) <0.001
Total emergencyc 0 (0–972) 507 (0–3932) <0.001
Total costsb 22 085 (8147) 69 414 (29 869) <0.001
Statistically signiﬁcant p value (<0.05).
aMedian (interquartile range).
bMean (standard deviation).
cMedian (minimum and maximum values).
dFrequency (%).
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by Bozic et al. had more outpatient visits (54.6 vs. 9.9).
While direct comparison of costs is not possible, overall
resource utilization in the Bozic study appears to be substan-
tially higher compared with our study [3]. Other economic
studies from the United States and Europe highlight the
increased costs associated with prosthetic joint infection.
Importantly, all these studies examine the cost of two-stage
exchange for management of infection; no study included
patients managed by debridement and retention of the pros-
thesis [12–17].
Debridement and retention of the prosthesis is an attrac-
tive management option in carefully selected patients with
prosthetic joint infection. Patients undergo fewer and less
extensive surgical procedures compared with two-stage
exchange, therefore decreasing operative-related morbidity.
Debridement and retention also is associated with shorter
duration of hospitalization and immobilization [1,18,19].
In a paper by Fisman et al., the cost-effectiveness of
debridement and retention compared with two-stage
exchange was assessed in a hypothetical cohort of patients
using a Markov model. In this study, the authors concluded
that debridement and retention was cost-effective, particu-
larly in older patients (>80 years old). The caveat to the
analysis by Fisman et al. is that the cost-effectiveness of
debridement and retention is sensitive to the rate of relapse
of infection [20]. Debridement and retention of the prosthe-
sis was most efﬁcacious when the annual relapse rate was
<19%. At SVHM, the published relapse rate is 6–11.76% and
in this current study only 5% of patients had suffered a
relapse of infection [5,7].
The strength of our study is that it is inclusive of all costs
associated with arthroplasty infection, including all acute
inpatient, rehabilitation and outpatient costs. The analysis
was also performed on a contemporary cohort of patients.
Our study has several limitations. First, it does not include
patients undergoing two-stage exchange for management of
infected arthroplasty. Over the study duration, only four
patients underwent two-stage exchange at SVHM. Two of
these patients underwent two-stage exchange for management
of infections associated with tumour megaprostheses. The
other two patients undergoing two-stage exchange were
excluded from analysis as the infections occurred following
revision arthroplasty and the entirety of their management was
not undertaken at SVHM. Therefore direct comparison of
costs associated with different management strategies was not
feasible. The preference for debridement and retention is not
limited to our institution; in a state-wide review of treatment
of prosthetic joint infections, 74% of patients with infection
were managed by debridement and retention (T. N. Peel, K. L.
Buising, A. C. Cheng, P. F. M. Choong, unpublished data).
Secondly, our analysis was restricted to a single centre.
While this design was advantageous to ensure complete
detailed costing data were available for all patients included,
it reduces the generalizablity of the data. In addition, at
SVHM the management of prosthetic joint infection is care-
fully protocolized with intensive collaboration between the
infectious diseases and orthopaedic clinicians. This enables
uniformity of management within our hospital, but overall
the heterogeneity in treatment approaches for debridement
and retention would lead to variation in overall cost data
between institutions. Finally, this analysis was restricted to
the direct medical costs to the patients and did not include
information pertaining to the patient perspective. Impor-
tantly, this study does not include non-medical and societal
costs associated with infection, which may be signiﬁcant.
With an ageing population and increasing demand for
arthroplasty, the number of patients undergoing prosthetic
joint surgery will escalate. Unfortunately, associated with
this, the number of patients with prosthetic joint infection
will likewise increase. The morbidity and mortality associated
with these infections has been well delineated. In contrast,
very little literature exists examining the economic impact of
prosthetic joint infection. Our study adds signiﬁcantly to the
growing body of evidence highlighting the substantial costs
associated with prosthetic joint infection.
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